RUNX1 and myeloproliferative neoplasm: RUNX1 mutational status did not significantly correlate with WBC count, hemoglobin, or peripheral blood and bone marrow blasts, or history of prior myelodysplastic syndrome or myeloproliferative neoplasms (MDS/MPN) or therapy-related AML (t-AML).